Tag Archive for: Clinical Trial

Resolution Therapeutics to host virtual R&D webinar alongside world leading clinical hepatologists Prof. Jonathan Fallowfield and Dr. Elliot Tapper

/in

Resolution leadership team joined by world leading clinical hepatologist Elliot Tapper, MD, FAASLD, and EMERALD Chief Investigator Professor Jonathan Fallowfield Edinburgh and London, UK, 27 August 2025 – Resolution Therapeutics (“Resolution” or “Company”), a clinical-stage biopharmaceutical company pioneering regenerative macrophage therapies to treat inflammatory and fibrotic diseases, today announces that it will host a virtual […]

Read more

Breye Therapeutics announces successful completion of its Phase 1b trial with danegaptide in patients with diabetic retinopathy

/in

Orally administered treatment was well tolerated, with early signs of clinical activity In models of non-proliferative diabetic retinopathy (NPDR), danegaptide has demonstrated protection against retinal capillary loss and vascular leakage Data support continued advancement into Phase 2 clinical evaluation Copenhagen, Denmark, 24 June 2025 – Breye Therapeutics ApS (Breye), a clinical-stage ophthalmology focused biopharmaceutical company […]

Read more

Alys Pharmaceuticals announces CTA submission for ALY-301, the first mast cell selective c-Kit inhibitor for treatment of Cold Urticaria

/in

ALY-301 is a first-in-class bispecific antibody targeting c-Kit and CD-203c with mast cell selectivity Designed to enable safe dosing in chronic conditions and deliver clinical proof-of concept in a Phase 1/1b study Boston, Massachusetts and Lausanne, Switzerland, 10 June 2025 – Alys Pharmaceuticals, Inc. (“Alys”), an immune-dermatology focused company, today announces the submission of a […]

Read more

Bionical Emas and Pharma Resources Announce Exclusive Global Clinical Trial Supply Partnership

/in

Strategic agreement secures access to essential oncology injectables for clinical trials as European shortages intensify LONDON, UK – 29 May 2025: Bionical Emas, a global provider of Clinical Trial Services, announces an exclusive global clinical trial supply agreement with Pharma Resources GmbH, German pharmaceutical company and marketing authorization holder, specialized in oncology. This strategic partnership […]

Read more

Vesper Bio achieves enrolment milestone in Phase Ib/IIa trial of lead candidate VES001 for frontotemporal dementia

/in

Phase Ib/IIa trial is to evaluate the efficacy of VES001 in asymptomatic patients with gene mutations that cause frontotemporal dementia A total of six participants have been enrolled in the trial across two sites – one in the Netherlands and one in the United Kingdom Copenhagen, Denmark, 09 May 2025 – Vesper Bio ApS (“Vesper” […]

Read more